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CONTENT ANALYSIS OF 
PHARMACOECONOMIC ADVERTISING IN 
SPECIALTY AND PRIMARY CARE JOURNALS
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1University of Southern California, Los Angeles, CA, USA; 
2Allergan, Inc., Irvine, CA, USA
BACKGROUND: As a result of increasing cost con-
sciousness in the health care system, pharmaceutical
manufacturers have come under pressure to demonstrate
the pharmacoeconomic benefits of their products to
health care providers and payers. OBJECTIVE: To ana-
lyze the content of economic and health-related-quality-
of-life appeals in drug advertisements in primary care and
specialty journals. METHODS: Advertisements from
specialty and primary care journals from June 1997 to
June 1999 were analyzed. Each message was classified by
the content of the appeal as one of eight economic or
quality-of-life categories: compliance; direct or indirect
economic; patient satisfaction; overall well being; or
physical, social or psychological function. Appeals were
also classified as explicit or implicit depending on their
use of economic or “quality of life” terms (e.g. “cost-
effective”). Data were also collected on which type of ref-
erence the appeal cited: none, data on file or published
reference. RESULTS: Sixty-one advertisements were in-
cluded in the analysis with a total of eighty messages. Ap-
peals were mainly implicit (85%) and related to direct
economic messages. Specialty journals had relatively
more messages appealing to compliance (29% vs. 8%)
while primary care journals had relatively more messages
appealing to psychological function (24% vs. 4%). Most
appeals cited a published reference to substantiate their
message (56%), but 24% of appeals cited no reference.
Primary care journals were more likely to cite published
references than specialty journals (66% vs. 47%). CON-
CLUSION: In the absence of clearly delineated regula-
tion by the FDA governing the advertising of economic
or quality-of-life-related messages, the pharmaceutical in-
dustry has focused on implicit messages, avoiding overt
appeals to “cost-effective”, “cost-benefit”, “cost-utility”,
“QALY” or “quality of life”.
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PRE-POST AND BETWEEN GROUP 
DIFFERENCES IN PATIENT OUTCOMES IN A 
PHARMACEUTICAL CARE
INTERVENTION PROJECT
Kamath TV, Chaikledkaew U, Johnson KA
Department of Pharmaceutical Economics and Policy, 
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OBJECTIVE: To determine the impact of pharmacist in-
tervention on various patient outcomes. METHODS:
201 patients belonging to one medical group were di-
vided into the experimental group (N  54) and the com-
parator group (N  147). 353 patients belonging to a
second medical group served as the control group. All pa-
tients were sent a baseline survey and a follow-up survey
after 6 months to gather data on demographics, compli-
ance, quality of care, satisfaction with pharmacy care and
disease specific quality of life. During the 6 month pe-
riod, the experimental group received specialized phar-
macist’s services, while the others received usual care.
Clinical data, compliance from prescription claims and
health care utilization data were collected separately. RE-
SULTS: Patient satisfaction with pharmacy services sig-
nificantly improved at follow-up for the experimental
group. The increase in satisfaction at follow-up was sig-
nificantly higher in the experimental group compared to
the comparator as well as the control groups. HbA1c
scores for diabetic patients were significantly improved in
the experimental (7.8 down to 6.7) group. Adherence to
some of the HEDIS guidelines was significantly higher in
the experimental group compared to the comparator
group. Percentage of high compliers (self-reported Morisky
score) significantly doubled at follow-up in the experi-
mental group ( 24.6% up to 52%) and percentage of low
compliers significantly decreased at follow-up (73.6%
down to 49.1%). The number of drug therapy problems
were detected and reduced by pharmacists’ intervention
in the experimental group. Pharmacists were also able to
successfully improve patient health behaviors related to
medication use in the experimental group. CONCLU-
SION: The pharmacists were successful in improving pa-
tient outcomes, thereby providing better patient care.
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Age related macular degeneration is the leading cause of
legal blindness among those over 50 years old in the
Western world and is estimated to affect 20–37% of peo-
ple aged over 75 years. The only treatment option to
date, for the more severe wet form, is laser therapy, but is
appropriate for only about 20% of cases. There are sev-
eral new therapies under investigation, including photo-
dynamic therapy (PDT) with verteporfin, an intravenous
infusion followed by timed activation of the verteporfin
with a specific light source. OBJECTIVE: To estimate ef-
fects of verteporfin in terms of vision years gained, a
measure suitable for economic evaluation. METHODS:
Data came from the one year follow-up of a two year
Phase III clinical trial of 609 patients randomized verte-
porfin or placebo. The analysis included only those with
predominantly Classic CNV secondary to AMD as this
subgroup will be the one initially indicated for therapy.
Survival analyses (controlling for baseline vision, age,
gender and prior treatment) using a Weibull parametric
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hazard function were run to estimate time to thresholds
of vision loss. The resulting hazards were used to inform
transition probabilities in a Markov model, to estimate
effects (discounted at 3%) for an average patient. RE-
SULTS: The estimate of vision years gained was 0.57
during the trial, and 0.82 at 5 years. Benefits decreased
with age and baseline visual acuity. CONCLUSION:
Based on one year data, the majority of benefit was esti-
mated to accrue within the trial time frame, and benefits
differ across subgroups. Treatment costs may be offset by
delaying costs of blindness.
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A key purpose in conducting pharmacoeconomic (PE)
and health outcomes (HO) research is to aid in the deci-
sion-making process. However, surprisingly few studies
within the literature have evaluated the relevance of this
information to decision-makers. OBJECTIVES: The pur-
pose of this study was to evaluate the relevance of PE and
HO information to health plan decision-makers in man-
aging the pharmacy benefit. METHODS: A qualitative
research method using telephone interviews on a conve-
nience sample of managed care and PBM decision-mak-
ers was used. Participants were presented with 16 hypo-
thetical statements incorporating key PE and HO concepts
and asked to judge the relevance of the statements. Re-
spondents were also prompted to provide a rationale for
their judgement. Questions relating to respondent’s train-
ing and familiarity with PE concepts were also included.
RESULTS: Over 80% of respondents (n  16) were
pharmacists, with one-third working for PBMs. State-
ments related to quality-of-life, cost-of-prevention, cost/
year of life saved, increased life expectancy, and 2-year
savings were relevant to 80% of respondents. Willing-
ness to pay (WTP), cost to society and global cost of ill-
ness statements were considered irrelevant by 35%. Re-
sponse trends to the above indicate that copays preclude
the relevance of WTP information; societal perspectives
are generally not relevant to benefit management, and
plan demographics are more relevant than global demo-
graphics. Statements related to PE modeling were rele-
vant provided that inputs and assumptions were perti-
nent to the user. Statements reported in terms of quality
adjusted life year were difficult for respondents to con-
ceptualize. CONCLUSIONS: These findings suggest that
some PE and HO information is more relevant than oth-
ers in the management of the pharmacy benefit.
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The pharmaceutical industry (PI) is a principal provider
of pharmacoeconomic (PE) data to health care organiza-
tions (HCOs). Therefore, assessing how this information
is perceived and used by HCOs from the PI perspective
can provide insights for future development of PE infor-
mation. OBJECTIVES: The purpose of this study was to
describe the PI perceptions regarding the use of PE infor-
mation by HCOs. METHODS: A structured phone inter-
view was conducted with PI personnel who routinely in-
teract with HCOs, including account managers, scientific
liaisons, and PE/outcomes research managers. Partici-
pants were asked to comment with regard to the fre-
quency of use and importance of various types of PE in-
formation that is provided to HCOs. RESULTS: A total
of 21 subjects were interviewed. About 95% stated that
the PE information provided to HCOs in the previous
year was helpful. The majority of respondents (76%)
stated PE information was considered by HCOs for most
or some decisions. There was significant variation when
asked whether PE articles were relevant, credible, and un-
derstandable to HCOs. Reprints of PE data and HCO-
specific information were most commonly listed as best-
received by HCOs. A majority (81%) also felt there were
barriers to using PE information in HCOs; “isolated fo-
cus on the pharmacy budget” was listed as the most com-
mon barrier. Only one-third of respondents felt their
company met the PE needs of HCOs. The remainder
listed lack of PE information as the primary cause for not
meeting the PE needs of HCOs. CONCLUSION: While
respondents felt that PE information is commonly used
and is perceived as valuable, this study has identified po-
tential limitations to the currently available information.
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Much emphasis is currently being placed on determining
the proper methodology for conducting economic analy-
ses of pharmaceuticals. However, perhaps equally impor-
tant is the need for consideration of how this information
is actually being used by decision-makers. The most re-
cent examination of this issue occurred in 1996. OBJEC-
TIVES: The purpose of this study was to increase our un-
derstanding of how pharmacoeconomic information is
used by decision-makers in managed care and to identify
perceived strengths and weaknesses of the available in-
formation given the current state of the pharmacy bene-
